微针经皮给药系统应用于皮肤肿瘤治疗的研究进展  

Advances in Research on Microneedle Transdermal Drug Delivery System Applied for Skin Tumor Treatment

作　　者：熊莎 赖蓉蓉 刘紫艺 徐月红[1] XIONG Sha;LAI Rongrong;LIU Ziyi;XU Yuehong(School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China)

机构地区：[1]中山大学药学院,广东广州510006

出　　处：《药学进展》2022年第2期128-137,共10页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.81973491);广东省基础与应用基础研究基金(No.2019A1515011161)。

摘　　要：经皮给药系统(TDDS)作为一种经表皮给药途径递药,近年来受到广泛关注。然而,皮肤的主要屏障角质层极大地限制了大部分药物的药效。微针(MNs)可穿透角质层,为药物经皮渗透创造瞬时微通道,从而递送药物至真皮层或皮下。同时MNs给药微创、操作简单、无痛且药物可控释放,因此在皮肤局部或全身给药具有广阔的应用前景。综述MNs的制备、分类及其应用于皮肤肿瘤治疗的最新研究进展,探讨MNs在生物医药研究领域的发展前景,为MNs经皮给药系统应用于临床提供参考。Transdermal drug delivery system(TDDS),as a percutaneous drug administration route,has received extensive attention in recent years.However,the existence of stratum corneum(SC),the main skin barrier,greatly limits the effects of most drugs.Microneedles(MNs)can penetrate the SC and create transient microchannels for drug percutaneous permeation,and subsequently deliver drugs to the dermis or subcutaneous layer.Meanwhile,administration of MNs is minimally invasive and easy to operate,with no pain and good control of drug release,so it has a broad application prospect for topical or systemic skin disease.The present paper mainly reviews the preparation and classification of MNs,and the latest progress of MNs in treating skin tumors,with further discussion about the development prospect of MNs in the field of biomedical research,which will provide reference for clinical application of MNs transdermal delivery system.

关 键 词：微针 经皮给药系统 皮肤肿瘤 

分 类 号：R739.5[医药卫生—肿瘤] R943[医药卫生—临床医学]